Payment overview · 2025
General Payments
$1,767.57
97 reported records · 20 companies
Healthcare provider profile · identity verified
Mikhail Kapchits, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · FOREST HILLS, NY · NPI 1467447235
Verified facts
What the public records show
CMS Open Payments records show Mikhail Kapchits, M.D. received $1,767.57 in general payments during 2025 across 97 reported records.
Novartis Pharmaceuticals Corporation accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Kerendia, Trelegy Ellipta, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 741 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1278 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 370 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1278 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $370.95 | 21.0% | 24 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $193.76 | 11.0% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.65 | 8.1% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $118.82 | 6.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $115.92 | 6.6% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $112.24 | 6.3% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $101.84 | 5.8% | 5 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $101.17 | 5.7% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.52 | 4.6% | 4 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $64.76 | 3.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.26 | 3.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.31 | 3.2% | 3 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $47.65 | 2.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.13 | 2.6% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $34.36 | 1.9% | 1 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $26.94 | 1.5% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $25.91 | 1.5% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $24.69 | 1.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.49 | 1.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.20 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,767.57 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $370.95 | 24 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $161.02 | 15 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $144.98 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $143.65 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $118.82 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $115.92 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $112.24 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $101.84 | 5 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $101.17 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $80.52 | 4 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $64.76 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $61.26 | 2 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $47.65 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $42.67 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $34.36 | 1 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $26.94 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $9.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1278 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 370 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 741 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 138 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
103 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
741 | 133 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1278 | 198 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
138 | 36 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
370 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1278 | 198 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1364 | 286 |
| Eliquis | Apixaban | 1278 | 198 |
| Metoprolol Succinate | Metoprolol Succinate | 945 | 167 |
| Jardiance | Empagliflozin | 741 | 133 |
| Spironolactone | Spironolactone | 711 | 144 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 676 | 165 |
| Nebivolol Hcl | Nebivolol Hcl | 615 | 127 |
| Carvedilol | Carvedilol | 586 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 511 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 498 | 99 |
| Hydralazine Hcl | Hydralazine Hcl | 491 | 84 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 425 | 90 |
| Entresto | Sacubitril/Valsartan | 370 | 64 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 335 | 60 |
| Amiodarone Hcl | Amiodarone Hcl | 307 | 48 |
| Eplerenone | Eplerenone | 303 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 291 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 289 | 72 |
| Bumetanide | Bumetanide | 288 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 288 | 63 |
| Sotalol | Sotalol Hcl | 243 | 43 |
| Losartan Potassium | Losartan Potassium | 236 | 55 |
| Xarelto | Rivaroxaban | 229 | 39 |
| Edarbi | Azilsartan Medoxomil | 217 | 35 |
| Nifedipine Er | Nifedipine | 214 | 51 |
| Bystolic | Nebivolol Hcl | 196 | 32 |
| Multaq | Dronedarone Hcl | 185 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 36 |
| Furosemide | Furosemide | 170 | 37 |
| Atenolol | Atenolol | 163 | 29 |
| Propranolol Hcl | Propranolol Hcl | 161 | 36 |
| Ranolazine Er | Ranolazine | 161 | 28 |
| Digoxin | Digoxin | 158 | 29 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 148 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 138 | 36 |
| Warfarin Sodium | Warfarin Sodium | 137 | 18 |
| Simvastatin | Simvastatin | 133 | 26 |
| Vascepa | Icosapent Ethyl | 133 | 28 |
| Midodrine Hcl | Midodrine Hcl | 130 | 32 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 121 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 118 | 20 |
| Metformin Hcl | Metformin Hcl | 114 | 35 |
| Ezetimibe | Ezetimibe | 110 | 20 |
| Trazodone Hcl | Trazodone Hcl | 109 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 105 | 25 |
| Linzess | Linaclotide | 103 | 18 |
| Repatha Sureclick | Evolocumab | 103 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 14 |
| Acarbose | Acarbose | 87 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 85 | 20 |
| Lisinopril | Lisinopril | 85 | 19 |
| Ramipril | Ramipril | 80 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 70 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 68 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 68 | 18 |
| Mounjaro | Tirzepatide | 60 | 14 |
| Nitroglycerin Patch | Nitroglycerin | 60 | 17 |
| Ozempic | Semaglutide | 60 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 58 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 55 | 16 |
| Rybelsus | Semaglutide | 55 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 53 | suppressed |
| Livalo | Pitavastatin Calcium | 49 | suppressed |
| Telmisartan | Telmisartan | 49 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 47 | 14 |
| Plavix | Clopidogrel Bisulfate | 46 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | suppressed |
| Verquvo | Vericiguat | 43 | suppressed |
| Crestor | Rosuvastatin Calcium | 41 | suppressed |
| Torsemide | Torsemide | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 39 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 39 | 11 |
| Allopurinol | Allopurinol | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Omeprazole | Omeprazole | 38 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Valsartan | Valsartan | 37 | 11 |
| Tribenzor | Olmesartan/Amlodipin/Hcthiazid | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Cilostazol | Cilostazol | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Lidocaine | Lidocaine | 32 | suppressed |
| Nisoldipine | Nisoldipine | 32 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Licart | Diclofenac Epolamine | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 28 | suppressed |
| Gabapentin | Gabapentin | 26 | suppressed |
| Indapamide | Indapamide | 26 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 16 |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Dexilant | Dexlansoprazole | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Norvasc | Amlodipine Besylate | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Benicar | Olmesartan Medoxomil | 23 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Droxidopa | Droxidopa | 22 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Praluent Pen | Alirocumab | 22 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 12 |
| Zenpep | Lipase/Protease/Amylase | 20 | suppressed |
| Ztlido | Lidocaine | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 17 | suppressed |
| Savaysa | Edoxaban Tosylate | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Zetia | Ezetimibe | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 14 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lovaza | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Disopyramide Phosphate | Disopyramide Phosphate | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Exelon | Rivastigmine | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lipitor | Atorvastatin Calcium | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Treximet | Sumatriptan Succ/Naproxen Sod | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,767.57 · 97 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, AVEIR, Attruby, CAMZYOS, CAPVAXIVE, ELIQUIS, ENTRESTO, FARXIGA, FFRct, FUROSCIX, INFINITY, INSPIRE, JARDIANCE, JOURNAVX, Kerendia, LEQVIO, NURTEC ODT, Paradise Ultrasound Renal Denervation System, REPATHA, REXULTI, SYMPLICITY G3, TELEPATCH CARDIAC MONITOR, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VYALEV | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error